Loading...
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Lung cancer is the leading cause of cancer death in the United States. The vast majority of patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5%. After first-line chemotherapy or biomarker-matched targeted therapy, only suitable for a small group of patients, fu...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066544/ https://ncbi.nlm.nih.gov/pubmed/27800034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016661164 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|